Structural characterization of P1′-diversified urea-based inhibitors of glutamate carboxypeptidase II

Abstract

Urea-based inhibitors of human glutamate carboxypeptidase II (GCPII) have advanced into clinical trials for imaging metastatic prostate cancer. In parallel efforts, agents with increased lipophilicity have been designed and evaluated for targeting GCPII residing within the neuraxis. Here we report the structural and computational characterization of six complexes between GCPII and P1′-diversified urea-based inhibitors that have the C-terminal glutamate replaced by more hydrophobic moieties. The X-ray structures are complemented by quantum mechanics calculations that provide a quantitative insight into the GCPII/inhibitor interactions. These data can be used for the rational design of novel glutamate-free GCPII inhibitors with tailored physicochemical properties.

The small molecule hyperphyllin enhances leaf formation rate and mimics shoot meristem integrity defects associated with AMP1 deficiency

“…However, so far we were unable to produce evidence for physical interaction between HP and AMP1, mainly because of the difficulties involved in generating recombinant AMP1 in sufficient quantity and quality to perform binding studies. HP does not contain residues found in known metalloprotease inhibitors such as zinc-chelating groups resistant to hydrolysis, including hydroxamate, sulphonate phosphonate, phosphinate, phosporamidate, or urea (Zhou et al, 2005;Pavlicek et al, 2014). Based on its small size, HP might rather bind to a subdomain of the substrate-binding pocket of AMP1 similar to the N-phenylbenzamide GW9662, which inhibits the binding of fatty acid ligands to peroxisome proliferator-activated receptor gamma (Chandra et al, 2008).…”

Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers

“…However, all such substitutions reported to date have failed to provide viable leads and instead have resulted in compounds with substantially lower PSMA affinities (9,(44)(45)(46). Likewise, a search for a new "ultimate" zinc-binding group has not been successful; consequently, ureido-based PSMA inhibitor scaffolds are currently the most prevalent theranostic PSMA-targeting vectors used, followed only by transition-state mimetics, such as phosphoramidates (47).…”

Enhanced semiempirical QM methods for biomolecular interactions

“…SQM-DH methods are now more and more often used for QM-based scoring [124,125] , QM/MM-based scoring [126,127] (sometimes unsuccessfully though still in good agreement with DFT [128] ) and the in silico design of biologically active compounds [129] . Two especially interesting studies need to be highlighted: In 2012 Stigliani et al presented a docking study based on Autodock Vina structures re-ranked with PM6-DH2/COSMO, clearly improving the results [130] .…”